UroGen Pharma (NasdaqGM:URGN) Earnings Call Presentation

ZUSDURI (formerly UGN-102) Approved by FDA! ZUSDURI is the first and only FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer Transforming Urothelial Cancer Care Through Innovation March 2026 Disclaimers This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the estimated addressable patient population and market and revenue opportunity for ...